Item 1.01Entry into a Material Definitive Agreement. Securities Purchase AgreementOn June 30, 2022, X4 Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with several institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 37,649,086 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) with respect to certain Investors, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 13,276,279 shares of(…)
The Latest Press Releases